Difference between revisions of "Cytarabine and daunorubicin liposomal (Vyxeos)"

Revision as of 19:20, 22 February 2019

This drug is a liposomal formulation of Cytarabine (Ara-C) and Daunorubicin (Cerubidine) in a 5:1 molar ratio. ^[1]^[2]^[3]
Route: IV
Extravasation: no information

8/3/2017: Granted FDA regular approval "for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis."

@@ Line 6: / Line 6: @@
 ==Disease for which it is used==
 *[[Acute myeloid leukemia]]
-<!-- Presented in part in abstract form at the 52nd annual meeting of the American Society of Hematology, Orlando, FL December 4-7, 2010. -->
-# Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239-46. Epub 2014 Mar 31. [http://bloodjournal.hematologylibrary.org/content/123/21/3239.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24687088 PubMed]
-# Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015 Jan 15;121(2):234-42. Epub 2014 Sep 15. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.28974/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25223583 PubMed]
 ==History of changes in FDA indication==